山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (9): 35-41.doi: 10.6040/j.issn.1671-7554.0.2022.0973
鹿群1,赵璐璐2
LU Qun1, ZHAO Lulu2
摘要： 子宫内膜癌及子宫内膜非典型增生的发病率逐渐升高,呈年轻化趋势,且保留生育功能的需求增加。以高效孕激素为基础的子宫内膜癌和子宫内膜非典型增生保留生育功能治疗方法能达到高的完全缓解率,但是生育力依然低下。以“妊娠为目的”积极助孕策略受到学者重视,但是关于子宫内膜癌和子宫内膜非典型增生保留生育功能后助孕缺乏系统研究。本文就保留生育功能治疗后助孕时机、助孕方案以及助孕中的难点进行探究。
中图分类号:
| [1] Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience[J]. Cancer Manag Res, 2018, 10:6803-6813. doi: 10.2147/CMAR.S188087. eCollection 2018. [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [4] Morice P, Leary A, Creutzberg C, et al. Endometrial cancer[J]. Lancet, 2016, 387(10023): 1094-1108. [5] Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383(21): 2053-2064. [6] 王建六.应重视和发展妇科肿瘤生殖学[J]. 中国临床医生杂志,2020,48(3): 253-254. [7] 肖泽睿,鹿群,周蓉,等.子宫内膜非典型增生及子宫内膜癌患者保留生育功能治疗的妊娠结局分析[J]. 中华妇产科杂志, 2020, 55(12)857-864. XIAO Zerui, LU Qun, ZHOU Rong, et al. Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma[J]. Chin J Obstet Gynecol, 2020, 55(12): 857-864. [8] Olga V Novikova, Vladimir B Nosov, Vladimir A Panov, et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer[J]. Gynecol Oncol, 2021, 161(1): 152-159. [9] 鹿群, 田莉, 沈浣, 等. 不孕症合并子宫内膜非典型增生患者助孕治疗的临床分析[J]. 中国妇产科临床杂志,2008,9(1): 27-30. LU Qun, TIAN Li, SHEN Huan, et al. Assisted reproductive treatment following conservative management of endometrial hyperplasia with atypia in infertile women[J]. Chin J Clin Obstet Gynecol, 2008, 9(1): 27-30. [10] 周蓉, 鹿群, 刘国莉, 等. 早期子宫内膜癌保留生育功能治疗专家共识[J].中国妇产科临床杂志, 2019,20(4): 369-373. [11] Matsuzaki T, Iwasa T, Kawakita T, et al. Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia[J]. Reprod Med Biol, 2018, 17(3): 325-328. [12] Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2012, 207(4): 266.e1-12. [13] Park JY, Seong SJ, Kim TJ, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer[J]. Obstet Gynecol, 2013, 121(1): 136-142. [14] Xiao ZR, Song ZY HM, Lu Q, et al. Pregnancy outcomes after fertility preservation in women with endometrial carcinoma and atypical endometrial hyperplasia: a systematic review and meta-analysis[J]. Gynecol Obstet Clin Med, 2021, 1(4): 190-196. [15] 杜晓果, 宋雪凌, 李蓉, 等. 不孕症合并子宫内膜非典型增生及早期高分化子宫内膜样腺癌保守治疗后体外受精助孕的临床分析[J]. 中华生殖与避孕杂志,2018, 38(9): 741-747. DU Xiaoguo, SONG Xueling, LI Rong, et al. Analysis of the clinical outcome of in vitro fertilization in infertility patients with conservative treatment of atypical endometrial hyperplasia and early well-differentiated endometrial adenocarcinoma[J]. Chinese Journal Reproduction Contraception, 2018, 38(9): 741-747. [16] Song Z, Liu H, Zhou R, et al. The optimal time for the initiation of in vitro fertilization and embryo transfer among women with atypical endometrial hyperplasia and endometrial carcinoma receiving fertility-sparing treatment[J]. Arch Gynecol Obstet, 2021, 305(5):1225-1223. [17] Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J]. J Clin Oncol, 1998, 16(2): 453-461. [18] Sh Tehrani Nejad E, Abediasl Z, Rashidi BH, et al. Comparison of the efficacy of the aromatase inhibitorletrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized,clinical trial[J]. J Assist Reprod Genet, 2008, 25(5): 187-190. [19] Maysoon Sharief, Najlaa Rasmee Nafee. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation[J]. J Pak Med Assoc, 2015, 65(11): 1149-1152. [20] 韩明, 宋字仪, 梁蓉, 等. 来曲唑在卵巢高反应患者促排卵中的应用[J]. 中国妇产科临床杂志,2021,22(4): 394-397. HAN Ming, SONG Ziyi, LIANG Rong, et al. Application of letrozole in ovarian stimulation for hyper-responders[J]. Chinese Journal of Clinical Obstetrics and Gynecology, 2021, 22(4): 394-397. [21] Kim JH, Kim SK, Lee HJ, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients[J]. J Korean Med Sci, 2015, 30(3): 290-295. [22] Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma[J]. Fertil Steril, 2007, 88(3): 657-664. [23] Chabbert-Buffeta N, Skinner DC, Caraty A, et al. Neuroendocrine effects of progesterone[J]. Steroids, 2000, 65(10-11): 613-620. [24] Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes(Shanghai protocol)[J]. Reprod Biomed Online, 2014, 29(6): 684-691. [25] Kuang Y, Chen Q, Fu Y, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization[J]. Fertil Steril, 2015, 104(1): 62-70. [26] Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF[J]. Hum Reprod Update, 2017, 23(2): A211-220. [27] Ata B, Capuzzo M, Turkgeldi E, et al. Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses[J]. Hum Reprod Update, 2021, 27(1): 48-66. [28] Adeleye AJ, Aghajanova L, Kao CN, et al. Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes[J]. Fertil Steril, 2018,110(1): 83-88. [29] 肖亚玲,孙正怡,王雪,等.早期子宫内膜癌和子宫内膜非典型增生患者保守治疗后的IVF-ET治疗结局[J].生殖医学杂志, 2021, 30(1):1-6. XIAO Yaling, SUN Zhengyi, WANG Xue, et al. IVF-ET outcome in patients with early endometrial cancer and atypical endometrial hyperplasia afterconservative treatment[J]. J Reprod Med, 2021, 30(1): 1-6. [30] Hu L, Du J, Lv H, et al. Influencing factors of pregnancy loss and survival probability of clinical pregnancies conceived through assisted reproductive technology[J]. Reprod Biol Endocrinol, 2018, 16(1): 74. [31] Kim MJ, Choe SA, Kim MK, et al. Outcomes of in vitro fertilization cycles following fertility-sparing treatment in stage IA endometrial cancer[J]. Arch Gynecol Obstet, 2019, 300(4): 975-980. [32] 武学清,孔蕊,田莉,等. 卵巢低反应专家共识[J]. 生殖与避孕, 2015, 35(2): 71-78. WU Xueqing, KONG Rui, TIAN Li, et al. A consensus of poor ovarian response[J]. Reproduction & Contraception, 2015, 35(2): 71-78. [33] Zhang Y, Zhang C, Shu J, et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis[J]. Hum Reprod Update, 2020, 26(2): 247-263. [34] 洪艳丽,谈勇,施艳秋,等.益气养阴方联合体外受精-胚胎移植对卵巢低反应患者卵细胞质量及妊娠结局的影响[J].中医杂志,2015,56(2): 115-119. [35] Hu L, Bu Z, Guo Y, et al. Comparison of different ovarian hyperstimulation protocols efficacy in poor ovarian responders according to the Bologna criteria[J]. Int J Clin Exp Med, 2014, 7(4): 1128-1134. [36] Huang P, Tang M, Qin A. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: a retrospective study[J]. J Gynecol Obstet Hum Reprod, 2019, 48(2): 99-102. [37] Han AR, Kwon YS, Kim DY, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia[J]. Int J Gynecol Cancer, 2009, 19(1): 147-151. [38] Inoue O, Hamatani T, Susumu N, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia[J]. Reprod Biol Endocrinol, 2016, 14: 2.doi: 10.1186/s12958-015-0136-7. [39] Chae SH, Shim SH, Lee SJ, et al. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer[J]. Int J Gynecol Cancer, 2019, 29(1): 77-85. [40] Kasius A, Smit JG, Torrance HL, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis[J]. Hum Reprod Update, 2014, 20(4): 530-541. [41] Tong XM, Lin XN, Jiang HF, et al. Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma[J]. Chin Med J(Engl), 2013, 126(15): 2965-2971. [42] Fujimoto A, Ichinose M, Harada M, et al. The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer[J]. J Assist Reprod Genet, 2014, 31(9): 1189-1194. [43] 赵璐璐, 鹿群, 周蓉, 等. 子宫内膜癌高效孕激素治疗后合并子宫内膜过薄中西医结合助孕成功一例[J].中国妇产科临床杂志,2019,20(4): 363-364. [44] Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study[J]. BMJ, 2007, 335(7630): 1134. [45] Jungheim ES, Moley KH. Current knowledge of obesitys effects in the pre- and periconceptional periods and avenues for future research[J]. Am J Obstet Gynecol, 2010, 203(6): 525-530. [46] Li M, Guo T, Cui R, et al. Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis[J]. Cancer Manag Res, 2019, 11: 4005-4021. doi:10.2147/CMAR.S194607. [47] Park JY, Seong SJ, Kim TJ, et al. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer[J]. Gynecol Oncol, 2017, 146(1): 39-43. [48] Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review[J]. Semin Reprod Med, 2011, 29(6): 507-513. [49] Gonthier C, Walker F, Luton D, et al. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer[J]. Gynecol Oncol, 2014, 133(1): 33-37. |
| [1] | 赵舸,邹存华,宋冬冬,赵淑萍. 丹参酮IIA对子宫内膜癌细胞增殖与凋亡的影响[J]. 山东大学学报 (医学版), 2022, 60(9): 53-58. |
| [2] | 刘腾,马迎春. 基于生物信息库病例分析ECT2在子宫内膜癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(8): 63-71. |
| [3] | 申晓畅,孙一卿,颜磊,赵兴波. 芳基烃受体核转位因子样蛋白2在子宫内膜癌中的表达[J]. 山东大学学报 (医学版), 2022, 60(5): 74-80. |
| [4] | 丁菲,姜洁. 姜黄素对子宫内膜癌孕激素抵抗的影响[J]. 山东大学学报 (医学版), 2021, 59(4): 35-41. |
| [5] | 杨旎,曹冬焱,杨佳欣,游燕,沈铿. 卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素[J]. 山东大学学报 (医学版), 2018, 56(5): 30-34. |
| [6] | 张颖,杨佳欣,曹冬焱,俞梅,沈铿,黄惠芳,潘凌亚,吴鸣,郎景和,游燕. 早期上皮性卵巢癌保留生育功能手术患者预后与妊娠状况的影响因素[J]. 山东大学学报 (医学版), 2018, 56(5): 13-17. |
| [7] | 赵珊,闫莉. 慢性肾功能衰竭合并异常子宫出血患者子宫内膜消融术后继发子宫内膜癌1例[J]. 山东大学学报 (医学版), 2018, 56(5): 91-92. |
| [8] | 杨佳欣,沈铿,王遥. 妇科恶性肿瘤保留生育功能治疗的现状与展望[J]. 山东大学学报 (医学版), 2018, 56(5): 1-7. |
| [9] | 俞梅,杨佳欣,曹冬焱,王遥,沈铿. 早期子宫内膜癌保留生育功能治疗后复发的诊治[J]. 山东大学学报 (医学版), 2018, 56(5): 23-29. |
| [10] | 曹冬焱,毕晓宁,沈铿. 抗苗勒氏管激素在妇科肿瘤领域的应用前景[J]. 山东大学学报 (医学版), 2018, 56(5): 8-12. |
| [11] | 张素萍,王泽,周亚丽, 李敬,路西兰,柏宏伟,石玉华. 来曲唑治疗不同体质量指数多囊卵巢综合征患者的临床效果[J]. 山东大学学报（医学版）, 2017, 55(5): 81-85. |
| [12] | 王甜甜,陈洁. EFEMP2在子宫内膜癌组织及细胞中的表达及其临床意义[J]. 山东大学学报（医学版）, 2017, 55(10): 52-58. |
| [13] | 路真真,颜磊,张辉,张晓晖,赵兴波. 肿瘤微环境中TGF β-1对子宫内膜间质细胞活化的影响[J]. 山东大学学报（医学版）, 2016, 54(9): 37-40. |
| [14] | 张明超, 聂云天. CDK8与E-cad在子宫内膜癌的发生、发展中的表达意义[J]. 山东大学学报（医学版）, 2014, 52(S1): 12-13. |
| [15] | 邓凯, 张成琪, 李伟, 王广丽, 董桂青, 史浩, 庞涛. 磁共振扩散加权成像诊断子宫内膜癌分期及与病理结果的相关性[J]. 山东大学学报（医学版）, 2014, 52(8): 81-84. |
|
